Literature DB >> 2647845

Increased secretion of immunoglobulins in malignant hypertension.

E Hilme1, H Herlitz, T Söderström, L Hansson.   

Abstract

Recent evidence suggests that immunogenic factors may be of importance for development and maintenance of severe hypertension. Twenty-three patients with a previously malignant phase of hypertension (MH) were investigated with respect to serum levels as well as actual production of immunoglobulins (lgs) and compared with a group of 22 patients with non-malignant hypertension (NMH) and 45 matched normotensive control subjects (C). Patients with MH had a significantly elevated secretion of IgG and IgA as compared with C. Total serum concentration of lgs did not differ between the groups, but a raised level of the subclass IgG3 was found in MH. There was a significant positive correlation between systolic blood pressure (SBP) and secretion of IgA and IgG when all hypertensive patients were studied. Six patients were subjected to repeated investigations during the first year after malignant phase. If examined in an early phase of MH (within 4 months) the secretion of IgG, IgA and IgM was enhanced compared with later stages (after 5-12 months). The results suggest that an immunological process is involved in MH. This could either be a primary immunological disturbance or more plausibly secondary effects due to the vascular damage caused by the very high blood pressure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647845

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  The immune system and hypertension.

Authors:  Madhu V Singh; Mark W Chapleau; Sailesh C Harwani; Francois M Abboud
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 2.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

Review 3.  Fcγ receptors and ligands and cardiovascular disease.

Authors:  Keiji Tanigaki; Nathan Sundgren; Amit Khera; Wanpen Vongpatanasin; Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2015-01-16       Impact factor: 17.367

Review 4.  Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications.

Authors:  Daniela Carnevale
Journal:  Nat Rev Cardiol       Date:  2022-03-17       Impact factor: 32.419

5.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

Review 6.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

Review 7.  Immune mechanisms of hypertension.

Authors:  Grant R Drummond; Antony Vinh; Tomasz J Guzik; Christopher G Sobey
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

Review 8.  Antibodies in the pathogenesis of hypertension.

Authors:  Christopher T Chan; Maggie Lieu; Ban-Hock Toh; Tin S Kyaw; Alexander Bobik; Christopher G Sobey; Grant R Drummond
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

Review 9.  Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair.

Authors:  Uma Maheswari Selvaraj; Katherine Poinsatte; Vanessa Torres; Sterling B Ortega; Ann M Stowe
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 10.  Immunity and Hypertension.

Authors:  Rong M Zhang; Kyle P McNerney; Amy E Riek; Carlos Bernal-Mizrachi
Journal:  Acta Physiol (Oxf)       Date:  2020-06-25       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.